Table 1.

Patient characteristics

PATIENT CHARACTERISTICSALL WARFARIN USERS (N = 13 481)THOSE WITH AF (N = 5010)THOSE WITH VTE (N = 730)
Female sex, n (%)6285 (46.6)2221 (44.3)379 (51.9)
Mean (SD) age, y71.9 (14.0)75.1 (11.3)63.1 (15.9)
Mean (SD) BMI, kg/m230.1 (6.8)30.2 (6.5)31.8 (7.3)
Mean (SD) GFR, mL/min64.7 (19.9)58.2 (16.7)56.3 (17.7)
Comorbidities, n (%)
  • Hypertension8103 (60.1)3349 (66.9)370 (50.7)
  • Osteoarthritis4852 (36.0)2149 (42.9)288 (39.5)
  • Diabetes4144 (30.7)1670 (33.3)178 (24.4)
  • Depression3075 (22.8)1061 (21.2)233 (31.9)
  • COPD2747 (20.4)1146 (22.9)125 (17.1)
  • Dementia1770 (13.1)731 (14.6)62 (8.5)
Warfarin-related condition, n (%)
  • AF5010 (37.2)5010 (100.0)184 (25.2)
  • DVT621 (4.6)160 (3.2)621 (85.1)
  • PE131 (1.0)33 (0.7)131 (18.0)
Medications, n (%)
  • ≥ 4 medications (including warfarin)7120 (52.8)2807 (56.0)292 (40.0)
  • Cardiovascular drugs9973 (74.0)4179 (83.4)340 (46.6)
  • Lipid-modifying drugs5779 (42.9)2187 (43.7)179 (24.5)
  • Drugs for acid disorders4323 (32.1)1707 (34.1)202 (27.7)
  • Drugs for COPD or asthma3085 (22.9)1213 (24.2)134 (18.4)
  • Antidepressants2961 (22.0)1029 (20.5)186 (25.5)
  • Thyroid-related drugs1975 (14.7)799 (16.0)73 (10.0)
  • Antiepileptics1743 (12.9)660 (13.2)125 (17.1)
  • Anxiolytics1510 (11.2)510 (10.2)62 (8.5)
  • ASA967 (7.2)499 (10.0)39 (5.3)
  • Other antiplatelets457 (3.4)165 (3.3)10 (1.4)
  • Psycholeptics576 (4.3)196 (3.9)46 (6.3)
  • Anti-dementia drugs381 (2.8)132 (2.6)5 (0.7)
  • AF—atrial fibrillation, ASA—acetylsalicylic acid, BMI—body mass index, COPD—chronic obstructive pulmonary disease, DVT—deep vein thrombosis, GFR—glomerular filtration rate, PE—pulmonary embolism, VTE—venous thromboembolism.